1. de Galiza BF, Delso G, Ter Voert EE, Huellner MW, Herrmann K, Veit-Haibach P. Multi-technique hybrid imaging in PET/CT and PET/MR: What does the future hold? Clin Radiol. 2016;71:660–72.
https://doi.org/10.1016/j.crad.2016.03.013
.
2. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med. 2003;44:1797–803.
3. Mottaghy FM, Sunderkotter C, Schubert R, Wohlfart P, Blumstein NM, Neumaier B, et al. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging. 2007;34:1355–64.
https://doi.org/10.1007/s00259-006-0358-1
.
4. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670–5.
5. Kuhl DE, Phelps ME, Hoffman EJ, Robinson GD Jr, MacDonald NS. Initial clinical experience with 18F-2-fluoro-2-deoxy-d-glucose for determination of local cerebral glucose utilization by emission computed tomography. Acta Neurol Scand Suppl. 1977;64:192–3.